(CercleFinance.com) – Nanobiotix announces that its partner LianBio has entered into an agreement to transfer to Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, the exclusive rights to develop and commercialize NBTXR3 in China, South Korea, Singapore and Thailand.
This rights transfer agreement consolidates the global development and commercialization rights of NBTXR3 with Janssen and simplifies the global alliance with Nanobiotix for the co-development and registration of its radioenhancer.
It includes the transfer of previously agreed economic terms, including the right for Nanobiotix to be eligible to receive up to a total of $220 million in contingent milestone payments, and double-digit tiered royalties on sales.